随机生存森林模型预测适合移植的新诊断多发性骨髓瘤结局:纳入FDG-PET影像组学的两项欧洲独立前瞻性试验联合分析
最终模型筛选出治疗臂、血红蛋白和骨髓SUVmax三个特征,可将患者分为预后良好和不良两组,平均风险比为4.3±1.5,平均log-rank P值为0.01±0.01;嵌套交叉验证分析证实了模型的稳健性。
要点
- 基线FDG-PET/CT的骨髓SUVmax联合治疗臂和血红蛋白可预测适合移植的新诊断多发性骨髓瘤患者的PFS。
- 随机生存森林模型将患者分为预后良好和不良两组,平均风险比4.3±1.5,平均log-rank P值0.01±0.01。
- 嵌套交叉验证显示模型在不同数据划分下稳健,筛选出的特征保持稳定。
核心结论
- 基于两种随机生存森林方法,提出了适合移植的新诊断多发性骨髓瘤患者诊断时的新预后模型。
研究设计与样本
- 分析IFM/DFCI2009和EMN02/HO95两项前瞻性随机III期试验的影像辅助研究(IMAJEM和EMN02/HO95)。
- 收集17个影像特征(视觉和定量)和5个临床/组织病理学参数,采用两种随机生存森林方法(训练/验证+测试及嵌套交叉验证)预测PFS。
主要发现
- 最终模型从22个初始特征中筛选出3个特征:治疗臂、血红蛋白和骨髓SUVmax。
- 模型定义预后良好和不良两组,平均风险比4.3±1.5,平均log-rank P值0.01±0.01。
- 嵌套交叉验证分析显示,训练/验证+测试方法筛选出的首批特征在各折中保持为首选,表明模型稳健。
关键数值与推荐
- 最终模型基于治疗臂、血红蛋白和骨髓SUVmax三个特征。
- 预后良好与不良组的平均风险比为4.3±1.5,平均log-rank P值为0.01±0.01。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is included in the International Myeloma Working Group (IMWG) imaging guidelines for the work-up at diagnosis and the follow-up of multiple myeloma (MM) notably because it is a reliable tool as a predictor of prognosis. Nevertheless, none of the published studies focusing on the prognostic value of PET-derived features at baseline consider tumor heterogeneity, which could be of high importance in MM. The aim of this study was to evaluate the prognostic value of baseline PET-derived features in transplant-eligible newly diagnosed (TEND) MM patients enrolled in two prospective independent European randomized phase III trials using an innovative statistical random survival forest (RSF) approach. METHODS: Imaging ancillary studies of IFM/DFCI2009 and EMN02/HO95 trials formed part of the present analysis (IMAJEM and EMN02/HO95, respectively). Among all patients initially enrolled in these studies, those with a positive baseline FDG-PET/CT imaging and focal bone lesions (FLs) and/or extramedullary disease (EMD) were included in the present analysis. A total of 17 image features (visual and quantitative, reflecting whole imaging characteristics) and 5 clinical/histopathological parameters were collected. The statistical analysis was conducted using two RSF approaches (train/validation + test and additional nested cross-validation) to predict progression-free survival (PFS). RESULTS: One hundred thirty-nine patients were considered for this study. The final model based on the first RSF (train/validation + test) approach selected 3 features (treatment arm, hemoglobin, and SUVmaxBone Marrow (BM)) among the 22 involved initially, and two risk groups of patients (good and poor prognosis) could be defined with a mean hazard ratio of 4.3 ± 1.5 and a mean log-rank p value of 0.01 ± 0.01. The additional RSF (nested cross-validation) analysis highlighted the robustness of the proposed model across different splits of the dataset. Indeed, the first features selected using the train/validation + test approach remained the first ones over the folds with the nested approach. CONCLUSION: We proposed a new prognosis model for TEND MM patients at diagnosis based on two RSF approaches. TRIAL REGISTRATION: IMAJEM: NCT01309334 and EMN02/HO95: NCT01134484.
引用
- Jamet B, Morvan L, Nanni C, et al. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2020. PMID: 33006656. doi:10.1007/s00259-020-05049-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。